Skip to main content
Medical Tools

Online Medical Tools — CDR Global

Printed on 9/4/2026

For informational purposes only. This is not medical advice.

Geriatrics

CDR Global

The Clinical Dementia Rating (CDR) is a clinician-rated staging system that integrates cognitive and functional information across core domains to estimate dementia severity. Global CDR stages are 0 (none), 0.5 (questionable), 1 (mild), 2 (moderate), and 3 (severe).

Login to FavoriteCompare with FAST Dementia

Formula: Global stage classification: 0, 0.5, 1, 2, or 3 (non-additive stage scale).

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free accountSign in

How It Works

1

Conduct structured informant interview and direct patient assessment across six CDR domains

The Clinical Dementia Rating (CDR) requires a semi-structured interview with both a reliable informant (caregiver, family member) and the patient. The informant interview covers observed changes in six cognitive and functional domains: (1) Memory — difficulty with recent events, repeating questions, forgetting appointments; (2) Orientation — getting lost in familiar environments, confusion about date, time, or place; (3) Judgment and problem solving — difficulty managing finances, medications, recognizing social situations, driving; (4) Community affairs — ability to engage in work, shopping, social activities, group meetings; (5) Home and hobbies — managing household tasks, pursuing hobbies, domestic activities; (6) Personal care — ability to manage bathing, dressing, continence, and feeding. The direct patient interview assesses memory (recent and remote), orientation (time, place, person), and general cognitive functions. Both interviews are typically completed in one session lasting 30-45 minutes.

2

Rate each domain and compute the CDR Sum of Boxes (CDR-SB)

Each of the six domains is independently rated on a 5-point scale: 0 = None (no impairment); 0.5 = Questionable impairment (borderline, not clearly dementia); 1 = Mild impairment; 2 = Moderate impairment; 3 = Severe impairment. Note: The Personal care domain cannot be scored 0.5 — only 0, 1, 2, or 3. The CDR Global Score is derived from the Memory domain as the primary domain, with the other five domains used to support or override this primary rating using structured decision rules. The CDR Sum of Boxes (CDR-SB) = sum of all six domain scores, range 0-18. CDR-SB provides a more sensitive, continuous measure of dementia severity compared to the global categorical score and is preferred for clinical trials as an outcome measure.

3

Interpret CDR Global Score and CDR-SB for clinical management

CDR Global Score interpretation: 0 = No cognitive impairment — normal cognitive aging, no clinical dementia diagnosis. 0.5 = Questionable/Very Mild dementia — close monitoring, early intervention, biomarker assessment if available, consider MCI diagnosis. 1 = Mild dementia — independence preserved for most activities but requires significant assistance; initiate cholinesterase inhibitor therapy if Alzheimer's disease; driving assessment; safety planning. 2 = Moderate dementia — requires supervision for most ADLs; extensive care needs, consider residential care options; re-evaluate driving, financial management, medication management. 3 = Severe dementia — complete care dependence; comfort-focused care, hospice consideration, nutrition/swallowing assessment. CDR-SB interpretation: 0.5-4 = Very mild to mild; 4.5-9 = Moderate; 9.5-18 = Severe.

Who Uses the CDR Global

Alzheimer's Disease and MCI Staging for Clinical Trials

Clinical trial investigators, pharmaceutical companies, Alzheimer's disease research coordinators

CDR is the most widely used staging tool in Alzheimer's disease clinical trials. Most major anti-amyloid trials (lecanemab, donanemab, aducanumab) used CDR 0.5-1 (questionable to mild dementia) as the primary eligibility criterion, combined with biomarker confirmation (amyloid PET or CSF). The CDR-SB is the most commonly used primary efficacy endpoint in Phase 2 and 3 Alzheimer's disease trials — the FDA-approved treatments lecanemab (Leqembi) and donanemab (Kisunla) both used CDR-SB as a co-primary outcome measure. A CDR-SB treatment difference of 0.45 points or more is considered clinically meaningful in current regulatory frameworks.

Memory Clinic Dementia Staging and Diagnosis Documentation

Geriatricians, neurologists, geriatric psychiatrists, memory clinic teams

CDR provides the gold-standard functional staging framework for dementia diagnosis documentation in memory clinics. While MMSE or MoCA measure cognitive performance, CDR captures how cognitive impairment affects real-world functioning — the essential element of a DSM-5 dementia diagnosis (major neurocognitive disorder). CDR 0.5 is commonly used to document mild cognitive impairment (MCI) or questionable dementia. CDR 1 documents mild dementia. CDR documentation at diagnosis and annual follow-up creates the longitudinal staging record for care planning and treatment evaluation.

Longitudinal Disease Monitoring and Cholinesterase Inhibitor Response

Geriatricians, neurologists, primary care physicians managing dementia

CDR provides a validated framework for monitoring dementia progression and treatment response. In patients treated with cholinesterase inhibitors (donepezil, rivastigmine, galantamine), serial CDR-SB at 6-12 month intervals documents treatment response. A CDR-SB worsening of less than 1 point per year suggests beneficial treatment effect. CDR-SB progression of 3 or more points per year in a patient on cholinesterase inhibitor therapy suggests inadequate treatment response and warrants medication review, dose adjustment, or treatment modification.

Capacity Assessment and Legal/Financial Planning

Geriatricians, geriatric psychiatrists, elder law attorneys, hospital social workers

CDR staging provides important context for decision-making capacity assessments and advance care planning. CDR 0.5-1 (mild dementia): most patients retain decision-making capacity for routine medical decisions but may require support for complex financial or legal decisions. CDR 2 (moderate dementia): capacity for complex financial and legal decisions is typically impaired; guardianship or durable power of attorney evaluation is often warranted. CDR 3 (severe dementia): decisional capacity is typically absent for all but the most basic preferences. Clinicians increasingly combine CDR with formal capacity assessment tools (MacCAT-T) for comprehensive capacity documentation.

Nursing Home Placement and Level of Care Planning

Social workers, care managers, nursing home placement coordinators, family advisors

CDR staging informs level of care decisions across the dementia care continuum. CDR 1 (mild dementia): community-based care with increasing support; day programs, home care, caregiver education. CDR 2 (moderate dementia): Memory care unit or assisted living with dementia specialization; increased supervision needs. CDR 3 (severe dementia): Nursing home or specialized late-stage dementia unit; comfort care focus; hospice eligibility assessment (concurrent with FAST stage 7 assessment).

Biomarker Integration and Preclinical Alzheimer's Disease

Neurologists, dementia specialists, clinical researchers in Alzheimer's prevention trials

In the era of Alzheimer's disease biomarker testing (amyloid PET, tau PET, CSF biomarkers, plasma biomarkers), CDR is used to characterize the clinical syndrome alongside biomarker profile. CDR 0 with positive amyloid biomarker = preclinical Alzheimer's disease (no clinical symptoms despite biological disease). CDR 0.5 with positive amyloid = MCI due to Alzheimer's disease (early clinical stage). CDR 1-3 with positive amyloid = clinical Alzheimer's disease at mild/moderate/severe stages. This CDR-biomarker framework is used in the NIA-AA 2018 research framework and emerging preventive intervention trials.

Pro Tips

1

Memory is the primary domain — other domains are secondary support criteria

In CDR scoring, the Memory domain serves as the anchor. If Memory is rated 1, the CDR Global Score is 1 unless three or more of the other five domains differ by more than one level. The CDR algorithm explicitly designates Memory as the primary domain because memory impairment is the defining feature of the most common dementia (Alzheimer's disease). When memory rating differs from other domain ratings, structured decision rules (Morris criteria) determine the final CDR Global Score — never simply average all six domains.

2

CDR 0.5 is not a clean binary line between normal and dementia

CDR 0.5 represents the questionable dementia zone — many individuals in this category have mild cognitive impairment (MCI) that may or may not progress to dementia. CDR 0.5 does not automatically indicate dementia diagnosis. Key differentiators: CDR 0.5 due to normal aging shows minor forgetfulness without functional impact. CDR 0.5 due to MCI shows consistent memory impairment with very mild functional changes. CDR 0.5 due to early Alzheimer's disease shows progressive trajectory on serial assessment and may have positive biomarkers. The clinical distinction requires longitudinal follow-up and, when available, biomarker assessment.

3

CDR Sum of Boxes is preferred over Global Score for tracking treatment response

The CDR Global Score (0, 0.5, 1, 2, 3) is a categorical scale with coarse intervals that is insensitive to small but clinically meaningful changes within a severity band. The CDR Sum of Boxes (CDR-SB, range 0-18) provides a continuous measure with greater sensitivity to change within severity stages. For serial monitoring of treatment response (cholinesterase inhibitors, anti-amyloid therapies), CDR-SB is the preferred metric. A CDR-SB change of 0.5-1.0 points is the minimum clinically important difference (MCID) for treatment response monitoring.

4

The informant interview is as important as the patient interview

CDR relies heavily on informant report for the four functional domains (Community affairs, Home and hobbies, Personal care, and partly Judgment/problem solving). A thorough informant interview asks about specific recent examples of impairment rather than global ratings — 'Tell me about the last time she tried to pay a bill — how did that go?' is more reliable than 'Is she impaired with finances?' Choose an informant with daily contact who has known the patient for several years — this provides the baseline comparison needed for CDR staging.

5

Document CDR at every key clinical decision point

CDR staging should be documented at: initial dementia evaluation (diagnosis baseline), 6-12 month follow-up visits, prior to any treatment initiation or change, at any significant functional change, and when care level decisions are being made. Serial CDR documentation creates the longitudinal record needed for clinical trial eligibility, regulatory treatment criteria, capacity assessments, and level of care transitions. CDR trajectory (stable, slowly progressive, rapidly progressive) is as clinically important as the absolute score.

6

Community affairs and home activities domains are often the most sensitive early indicators

While Memory is the primary CDR domain, the Community affairs and Home and hobbies domains often show the earliest and most practically significant functional changes in early dementia. Changes in complex activities — reduced work performance, difficulty with finances, giving up driving, withdrawal from hobbies — may precede clear memory complaints in some patients. In CDR 0.5 cases where global staging is uncertain, a thorough Community affairs interview often clarifies whether functional impairment is present.

7

Modify the interview approach for CDR 2-3 patients

In moderate-to-severe dementia (CDR 2-3), direct patient interview is less informative because patients cannot reliably self-report. Place greater emphasis on the informant interview for all six domains. During the direct patient assessment, focus on observable behaviors (orientation, recent memory testing with simple recall tasks, basic attention) rather than complex reasoning questions. The informant's account of daily care needs, behavioral patterns, and functional dependencies provides the most reliable CDR domain information in advanced dementia.

Common Questions About Your Results

Evidence-Based Methodology

CDR is an extensively used dementia staging framework in clinical care and research, especially for Alzheimer's disease severity stratification.

Clinical Content Trust

Last reviewed:
April 21, 2026
Guideline version:
General evidence framework v2026.04
Source set version:
Primary-source set v1

How to Interpret Your Result

Higher CDR stages indicate greater dementia severity and increasing dependence on support for daily functioning.

When to Use This Tool

Use in dementia evaluation and follow-up to communicate overall severity and guide prognosis, care planning, and resource allocation.

Limitations

CDR depends on structured clinician judgment and collateral history quality; cross-rater consistency and context are important.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Sources

  1. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules.
  2. Hughes CP, et al. A new clinical scale for the staging of dementia.

Changelog

  1. April 21, 2026 · trust-baseline

    Clinical trust metadata enabled for this tool page with structured review/version fields.

Frequently Asked Questions